Literature DB >> 14722444

Psychomotor slowing in hepatitis C and HIV infection.

Hans-Jürgen von Giesen1, Tobias Heintges, Naghme Abbasi-Boroudjeni, Seher Kücükköylü, Hubertus Köller, Bernhard A Haslinger, Mark Oette, Gabriele Arendt.   

Abstract

BACKGROUND: Both HIV and hepatitis C virus (HCV) may enter the central nervous system and cause cognitive and/or motor dysfunction. There are limited data on cognition and no data on motor performance in HIV/HCV-coinfected patients.
OBJECTIVE: To provide data on cognition and motor performance in HIV/HCV infected patients.
METHODS: We compared 43 HIV-seropositive but HCV-seronegative patients, 43 HIV/HCV-coinfected patients, and 44 HIV-negative but HCV-positive patients, all of whom went through neuropsychologic testing and electrophysiologic assessment of basal ganglia-mediated motor function.
RESULTS: No significant differences could be found among the groups with regard to premorbid verbal and actual nonverbal intelligence, attention, and memory; the HIV dementia scale; and all somatic and most psychiatric complaints. Affective disorders were less frequent in HIV-negative but HCV-positive patients. This group also scored lower for depression. For all 3 groups, significant pathologic slowing of most rapid alternating movements (right hand) compared with those of HIV/HCV-negative controls as well as significantly prolonged contraction times (both hands) could be diagnosed. Simple reaction times were significantly prolonged only in HIV/HCV-coinfected patients.
CONCLUSIONS: Although clinically asymptomatic, both HIV-positive and HCV-positive patients may show affective disturbances and significant psychomotor slowing. A potential predictive value for the further course of infection, which is well established in HIV-positive patients, remains to be investigated in HCV-positive or HIV/HCV-coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722444     DOI: 10.1097/00126334-200402010-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Clinical contributors to cerebral white matter integrity in HIV-infected individuals.

Authors:  Assawin Gongvatana; Ronald A Cohen; Stephen Correia; Kathryn N Devlin; Jadrian Miles; Hakmook Kang; Hernando Ombao; Bradford Navia; David H Laidlaw; Karen T Tashima
Journal:  J Neurovirol       Date:  2011-10-01       Impact factor: 2.643

Review 2.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

3.  Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients.

Authors:  David F Tate; Jared Conley; Robert H Paul; Kathryn Coop; Song Zhang; Wenjin Zhou; David H Laidlaw; Lynn E Taylor; Timothy Flanigan; Bradford Navia; Ronald Cohen; Karen Tashima
Journal:  Brain Imaging Behav       Date:  2010-01-19       Impact factor: 3.978

4.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

5.  Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients.

Authors:  Jeanie C Yoon; Paul K Crane; Paul S Ciechanowski; Robert D Harrington; Mari M Kitahata; Heidi M Crane
Journal:  AIDS Care       Date:  2011-05-23

6.  Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.

Authors:  Theodore R Miller; Jeffrey J Weiss; Norbert Bräu; Douglas T Dieterich; Alicia Stivala; Monica Rivera-Mindt
Journal:  J Neurovirol       Date:  2016-11-28       Impact factor: 2.643

7.  The impact of human immune deficiency virus and hepatitis C coinfection on white matter microstructural integrity.

Authors:  J M Heaps-Woodruff; P W Wright; B M Ances; D Clifford; R H Paul
Journal:  J Neurovirol       Date:  2015-12-21       Impact factor: 2.643

Review 8.  [HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management].

Authors:  C Eggers
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

9.  Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health.

Authors:  Felix Kleefeld; Sophie Heller; Patrick Ingiliz; Heiko Jessen; Anders Petersen; Ute Kopp; Antje Kraft; Katrin Hahn
Journal:  J Neurovirol       Date:  2018-05-21       Impact factor: 2.643

10.  Neurocognition in individuals co-infected with HIV and hepatitis C.

Authors:  Charles H Hinkin; Steven A Castellon; Andrew J Levine; Terry R Barclay; Elyse J Singer
Journal:  J Addict Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.